ChiCTR2500099062 版本V1.0 版本创建时间2025/03/18 10:37:33 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500099062 

最近更新日期:

Date of Last Refreshed on:

2025-03-18 10:36:51 

注册时间:

Date of Registration:

2025-03-18 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

TNF-α抑制剂对克罗恩病手术患者的影响的临床研究

Public title:

Clinical study of the effect of TNF-alpha inhibitors on patients undergoing surgery for Crohn's disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

TNF-α抑制剂对克罗恩病手术患者的影响的临床研究

Scientific title:

Clinical study of the effect of TNF-alpha inhibitors on patients undergoing surgery for Crohn's disease

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙晓敏 

研究负责人:

孙晓敏 

Applicant:

Sun Xiaomin 

Study leader:

Sun Xiaomin 

申请注册联系人电话:

Applicant telephone:

+86 189 1828 9238

研究负责人电话:

Study leader's
telephone:

+86 189 1828 9238

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sxmglcly@163.com

研究负责人电子邮件:

Study leader's E-mail:

sxmglcly@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市静安区延长中路301号

研究负责人通讯地址:

上海市静安区延长中路301号

Applicant address:

No. 301 Middle Yanchang Road, Shanghai, China.

Study leader's address:

No. 301 Middle Yanchang Road, Shanghai, China.

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

同济大学附属第十人民医院

Applicant's institution:

Tongji University Tenth People's Hospital: Shanghai Tenth People's Hospital

研究负责人所在单位:

同济大学附属第十人民医院

Affiliation of the Leader:

Tongji University Tenth People's Hospital: Shanghai Tenth People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SHSY-IEC-5.0/23K11/P01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市第十人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai 10th People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-01-30 00:00:00

伦理委员会联系人:

孙奋勇

Contact Name of the ethic committee:

Sun Fenyong

伦理委员会联系地址:

上海市静安区延长中路301号

Contact Address of the ethic committee:

No. 301 Middle Yanchang Road, Shanghai, China.

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 6630 1604

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

同济大学附属第十人民医院

Primary sponsor:

Sun Xiaomin Tongji University Tenth People's Hospital: Shanghai Tenth People's Hospital

研究实施负责(组长)单位地址:

上海市静安区延长中路301号

Primary sponsor's address:

No. 301 Middle Yanchang Road, Shanghai, China.

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

同济大学附属第十人民医院

具体地址:

上海市静安区延长中路301号

Institution
hospital:

Tongji University Tenth People's Hospital: Shanghai Tenth People's Hospital

Address:

No. 301 Middle Yanchang Road, Shanghai, China.

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-selected project (self-funded)

研究疾病:

克罗恩病  

Target disease:

Crohn's disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

(1)获得克罗恩病手术患者的临床特征; (2)明确克罗恩病患者术前、术后应用抗TNF-α类药物的安全性和有效性。  

Objectives of Study:

(1) To obtain the clinical characteristics of patients undergoing surgery for Crohn's disease; (2) To determine the safety and efficacy of anti-TNF-α drugs before and after operation in patients with Crohn's disease.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①根据临床、影像学、内镜及术后病理学等检查明确诊断的克罗恩病患者。 ②首次在我院炎症性肠病外科中心行肠切除手术的患者。

Inclusion criteria

1. Patients with a clear diagnosis of Crohn's disease based on clinical, imaging, endoscopic and post-operative pathology; 2. Patients undergoing bowel resection for the first time at our Inflammatory Bowel Disease Surgery Centre.

排除标准:

①单纯行肛周手术和脓肿引流等手术。 ②因术后并发症行非计划性再手术(如因术后出血、吻合口漏、腹腔脓肿及造口并发症等而进行的手术。 ③临床资料不全或随访脱失。

Exclusion criteria:

1. Surgery for purely perineal surgery and abscess drainage, etc; 2. Unplanned reoperation for postoperative complications (e.g. surgery for postoperative bleeding, anastomotic leak, abdominal abscess and stoma complications; 3.Incomplete clinical information or loss of follow-up.

研究实施时间:

Study execute time:

From 2023-02-01 00:00:00 To 2023-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-02-01 00:00:00 To 2023-03-31 00:00:00

干预措施:

Interventions:

组别:

TNFi-暴露组 和 TNFi-未暴露组

样本量:

202

Group:

TNFi-exposed and TNFi-naive

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

同济大学附属第十人民医院 

单位级别:

三甲 

Institution
hospital:

Tongji University Tenth People's Hospital: Shanghai Tenth People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术前TNF-α抑制剂暴露对患者术后并发症的影响

指标类型:

主要指标

Outcome:

Effect of preoperative TNF-α inhibitor exposure on postoperative complications in patients

Type:

Primary indicator

测量时间点:

术后一个月和术后一年

测量方法:

统计出现术后并发症的患者占比

Measure time point of outcome:

One month and one year post-operative

Measure method:

Statistics on the percentage of patients with post-operative complications

指标中文名:

术后TNF-α抑制剂暴露对患者术后内镜复发的影响

指标类型:

主要指标

Outcome:

Effect of postoperative TNF-α inhibitor exposure on postoperative endoscopic recurrence in patient

Type:

Primary indicator

测量时间点:

术后半年和一年

测量方法:

统计出现术后内镜复发的患者占比

Measure time point of outcome:

Six months and one year post-operative

Measure method:

Statistics on the percentage of patients presenting with post-operative endoscopic recurrence

指标中文名:

术前TNF-α抑制剂暴露对患者手术方式的影响

指标类型:

次要指标

Outcome:

The effect of preoperative TNF-alpha inhibitor exposure on patients' surgical approach

Type:

Secondary indicator

测量时间点:

术后

测量方法:

统计不同手术方式的患者占比

Measure time point of outcome:

Post-operative

Measure method:

Statistics on the percentage of patients with different surgical procedures

指标中文名:

术前TNF-α抑制剂暴露对患者术后住院时间的影响

指标类型:

次要指标

Outcome:

The effect of preoperative TNF-alpha inhibitor exposure on patients' postoperative length of stay

Type:

Secondary indicator

测量时间点:

出院时间

测量方法:

统计患者术后住院时间(天)

Measure time point of outcome:

Time of discharge

Measure method:

Length of stay of statistical patients after surgery (days)

指标中文名:

术后TNF-α抑制剂暴露对患者术后并发症的影响

指标类型:

次要指标

Outcome:

Effect of postoperative TNF-α inhibitor exposure on postoperative complications in patients

Type:

Secondary indicator

测量时间点:

术后一年

测量方法:

统计出现术后并发症的患者占比

Measure time point of outcome:

One year post-operative

Measure method:

Statistics on the percentage of patients with post-operative complications

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后6个月内,有意向者通过邮箱(sxmglcly@163.com)合理要求获得

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within 6 months after the end of the study, interested parties can obtain it through a reasonable request by email (sxmglcly@163.com)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-03-18 10:36:51